Harrow Reports 58% Reduction in Patient-Reported Discomfort with IHEEZO®
NASHVILLE, Tennessee, August 20, 2026 Harrow, Inc. announced positive results from a prospective, randomized contralateral-eye study evaluating IHEEZO® (chloroprocaine...
Harrow
Advertisement
Harrow Acquires TYRVAYA Global Rights, Expands Dry Eye Portfolio
NASHVILLE, Tenn., August 6, 2026 Harrow Inc. announced it has entered into a definitive agreement to acquire the global...
Samsung Bioepis and Harrow Strengthen SB11 Clinical Evidence
INCHEON, South Korea & NASHVILLE, Tenn., July 20, 2026 Samsung Bioepis Co., Ltd. and Harrow, Inc. have presented positive...
Harrow Highlights New IHEEZO and BYOOVIZ Clinical Evidence at ASRS 2026
NASHVILLE, Tenn., July 20, 2026 Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America,...
Advertisement
